<DOC>
	<DOC>NCT00075270</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.</brief_summary>
	<brief_title>Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criteria: Signed Informed Consent Able to swallow an oral medication Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram Adequate kidney and liver function Adequate bone marrow function Tumor tissue available for testing Prior adjuvant or neoadjuvant therapy is permitted with an anthracycline or anthracenedionecontaining regimen however, subjects must have had cumulative doses of less than 360 mg/m2 of doxorubicin, 720 mg/m2 of epirubicin, or 72 mg/m2 of mitoxantrone No Her2/neu overexpression in tumor tissue tested or status unknown if tissue has never been tested Exclusion criteria: Prior treatment regimens for advanced or metastatic breast cancer. Pregnant or lactating Conditions that would effect the absorption of an oral drug Active infection Brain metastases Treatment with EGFR (Endothelial Growth Factor Receptor) inhibitor. Known hypersensitivity to Taxol or excipients of Taxol Peripheral neuropathy of Grade 2 or greater is not permitted Severe Cardiovascular disease or cardiac disease requiring a device. Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>ErbB1</keyword>
	<keyword>kinase inhibitor</keyword>
	<keyword>ErbB2</keyword>
	<keyword>EGFR</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Her2-neu</keyword>
</DOC>